• Activiomics appoints industry specialist to Board
    Dr Trevor Nicholls

News & Views

Activiomics appoints industry specialist to Board

Apr 07 2012

Activiomics Limited, a developer of biomarker technologies has appointed Dr Trevor Nicholls to its Board as Non-Executive Chairman.
Dr Nicholls has over 30 years’ experience of building international businesses in the life science industry. Currently he is CEO of CABI, a not-for-profit inter-governmental organisation owned by 46 member countries worldwide and is Non-Executive Chairman of Oxford Nanopore Technologies, which is developing the GridION system, a new generation of electronic molecular analysis system for use in scientific research, personalised medicine, crop science, and security/defence. His previous board roles include Chief Commercial Officer of Affymetrix Inc, based in California and as CEO of Oxagen, a UK biotech company for which he secured major commercial partnerships and academic collaborations.

Welcoming Dr Nicholls to the board, Dr Mark Warne, CEO of Activiomics, said: “I am confident that Trevor’s broad background in leading companies as they develop commercially will be invaluable to Activiomics as we move to the next phase of our development. He brings both a depth of international experience in commercial markets as well as a proven ability in raising finance for early-stage companies.”

Activiomics has developed innovative technologies using mass spectrometry to interrogate and interpret the activity of whole cell signalling pathways. This technology is well-positioned to support personalised medicine initiatives, which are influencing increasing numbers of therapeutic programs.

The Company has recently met internal milestones resulting in a second tranche of funding from IP Group plc, a developer of intellectual property based businesses. This follows an initial investment by IP Group in 2011.
Dr Nicholls said: “The unique nature of Activiomics’ approach to identifying robust biomarkers has already been validated by a number of partnerships with large pharmas, including with GlaxoSmithKline, UCB and Genentech, and the Company is well placed to take advantage of the rapidly growing personalised medicine market. I am delighted to be joining the Board at a time when it has received a financing injection on the back of this success and look forward to helping the company in its next stage of development.”
 


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events